29 drugs reach their earliest generic-entry date in 2043

Jan 2043 · 12

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Daptomycin · 2 strengths daptomycin	daptomycin	Hikma	217415	9 Jan 2043	patent
Alyftrek deutivacaftor; tezacaftor; vanzacaftor calcium	deutivacaftor; tezacaftor; vanzacaftor calcium	Vertex Pharms Inc	218730	10 Jan 2043	patent, carve-out possible
Hydromorphone Hydrochloride hydromorphone hydrochloride	hydromorphone hydrochloride	Hikma	217812	10 Jan 2043	patent
Crenessity crinecerfont	crinecerfont	Neurocrine	218820	12 Jan 2043	patent
Crenessity · 3 strengths crinecerfont	crinecerfont	Neurocrine	218808	12 Jan 2043	patent
Daybue trofinetide	trofinetide	Acadia Pharms Inc	217026	12 Jan 2043	patent
Daybue Stix · 3 strengths trofinetide	trofinetide	Acadia Pharms Inc	219884	12 Jan 2043	patent
Igalmi · 2 strengths dexmedetomidine hydrochloride	dexmedetomidine hydrochloride	Bioxcel	215390	12 Jan 2043	patent, carve-out possible
Brukinsa zanubrutinib	zanubrutinib	Beone Medicines Usa	218785	19 Jan 2043	patent, carve-out possible
Rhapsido remibrutinib	remibrutinib	Novartis	218436	19 Jan 2043	patent, carve-out possible
Auvelity · 2 strengths bupropion hydrochloride; dextromethorphan hydrobromide	bupropion hydrochloride; dextromethorphan hydrobromide	Axsome	215430	20 Jan 2043	patent, carve-out possible
Tarpeyo budesonide	budesonide	Calliditas	215935	23 Jan 2043	patent

Feb 2043 · 4

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Sotyktu deucravacitinib	deucravacitinib	Bristol	214958	11 Feb 2043	patent
Evdi trabectedin	trabectedin	Apotex	220837	18 Feb 2043	patent
Khindivi hydrocortisone	hydrocortisone	Eton	218980	23 Feb 2043	patent
Qulipta atogepant	atogepant	Abbvie	215206	27 Feb 2043	patent, carve-out possible

Mar 2043 · 1

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Vanrafia atrasentan hydrochloride	atrasentan hydrochloride	Novartis	219208	25 Mar 2043	patent, carve-out possible

Apr 2043 · 1

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Gavreto pralsetinib	pralsetinib	Rigel Pharms	213721	19 Apr 2043	patent

May 2043 · 2

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Metaxalone metaxalone	metaxalone	Primus Pharms	022503	14 May 2043	patent
Ogsiveo · 2 strengths nirogacestat hydrobromide	nirogacestat hydrobromide	Springworks	217677	19 May 2043	patent, carve-out possible

Jun 2043 · 1

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Vigafyde vigabatrin	vigabatrin	Pyros Pharms	217684	8 Jun 2043	patent

Aug 2043 · 1

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Krazati adagrasib	adagrasib	Bristol	216340	21 Aug 2043	patent

Sep 2043 · 1

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Akeega · 2 strengths abiraterone acetate; niraparib tosylate	abiraterone acetate; niraparib tosylate	Janssen Biotech	216793	30 Sep 2043	patent, carve-out possible

Oct 2043 · 4

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Nextstellis drospirenone; estetrol	drospirenone; estetrol	Mayne Pharma	214154	1 Oct 2043	patent, carve-out possible
Livmarli · 4 strengths maralixibat chloride	maralixibat chloride	Mirum	219485	5 Oct 2043	patent
Livtencity maribavir	maribavir	Takeda Pharms Usa	215596	11 Oct 2043	patent
Purified Cortrophin Gel corticotropin	corticotropin	Ani Pharms	008975	27 Oct 2043	patent

Nov 2043 · 1

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Hyrnuo sevabertinib	sevabertinib	Bayer Healthcare	219972	14 Nov 2043	patent

Dec 2043 · 1

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Ameluz aminolevulinic acid hydrochloride	aminolevulinic acid hydrochloride	Biofrontera	208081	8 Dec 2043	patent